Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.7609
-0.0211 (-2.70%)
Mar 3, 2026, 4:00 PM EST - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
5.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| XTL Biopharmaceuticals | 968.00K |
| Aprea Therapeutics | 488.24K |
| Silo Pharma | 72.10K |
CLDI News
- 11 days ago - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - GlobeNewsWire
- 19 days ago - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 6 months ago - Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 6 months ago - Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewsWire
- 7 months ago - Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 7 months ago - Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - GlobeNewsWire